Description: A psychedelic drug development company designing altered states of consciousness for mental health therapeutics.
The acute subjective experience of an altered conscious state is central to treatment outcomes.
There is no translational model to distinguish among different altered states of consciousness.
We’re mapping the biological basis of the varieties of psychedelic experience to enable precision design of modified conscious states.
PsyMed Ventures - Frontier Mental Health Venture Capital Fund
Empath Ventures | Funding the future of psychedelic medicine.
K50 Ventures - Pre-seed capital for purpose-driven companies
PsyMed Ventures - Frontier Mental Health Venture Capital Fund